These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29335342)

  • 1. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
    Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
    Murray C; Fearon C; Dockery M; Moran D; Heffernan E; Fitzgerald O; Veale DJ; Harty L
    Ir Med J; 2018 Oct; 111(9):820. PubMed ID: 30556668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
    Lin Z; Gu J; He P; Gao J; Zuo X; Ye Z; Shao F; Zhan F; Lin J; Li L; Wei Y; Xu M; Liao Z; Lin Q
    Rheumatol Int; 2011 Feb; 31(2):233-8. PubMed ID: 20012866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis.
    Dong X; Zheng Y; Shi TY; Liu HY
    Clin Rheumatol; 2015 May; 34(5):915-20. PubMed ID: 25064131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
    Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
    J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.